Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease
Fløisand, Yngvar ; Lundin, Knut E A ; Lazarevic, Vladimir LU
; Kristiansen, Jørn Dehli
; Osnes, Liv T N
; Tjønnfjord, Geir E.
; Reims, Henrik Mikael
and Gedde-Dahl, Tobias
(2017)
In Biology of Blood and Marrow Transplantation
23(1).
p.172-175
- Abstract
Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7f11bab7-3356-4615-82e4-48cb033ebcc8
- author
- Fløisand, Yngvar
; Lundin, Knut E A
; Lazarevic, Vladimir
LU
; Kristiansen, Jørn Dehli
; Osnes, Liv T N
; Tjønnfjord, Geir E.
; Reims, Henrik Mikael
and Gedde-Dahl, Tobias
- publishing date
- 2017-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Graft-versus-host disease, Gut GVHD, Integrin, Stem cell transplant, Steroid refractory, Vedolizumab
- in
- Biology of Blood and Marrow Transplantation
- volume
- 23
- issue
- 1
- pages
- 4 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:27777142
- scopus:85006351875
- ISSN
- 1083-8791
- DOI
- 10.1016/j.bbmt.2016.10.009
- language
- English
- LU publication?
- no
- id
- 7f11bab7-3356-4615-82e4-48cb033ebcc8
- date added to LUP
- 2017-01-16 09:57:02
- date last changed
- 2025-10-14 09:06:05
@article{7f11bab7-3356-4615-82e4-48cb033ebcc8,
abstract = {{<p>Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.</p>}},
author = {{Fløisand, Yngvar and Lundin, Knut E A and Lazarevic, Vladimir and Kristiansen, Jørn Dehli and Osnes, Liv T N and Tjønnfjord, Geir E. and Reims, Henrik Mikael and Gedde-Dahl, Tobias}},
issn = {{1083-8791}},
keywords = {{Graft-versus-host disease; Gut GVHD; Integrin; Stem cell transplant; Steroid refractory; Vedolizumab}},
language = {{eng}},
month = {{01}},
number = {{1}},
pages = {{172--175}},
publisher = {{Elsevier}},
series = {{Biology of Blood and Marrow Transplantation}},
title = {{Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease}},
url = {{http://dx.doi.org/10.1016/j.bbmt.2016.10.009}},
doi = {{10.1016/j.bbmt.2016.10.009}},
volume = {{23}},
year = {{2017}},
}